2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with a 42% revenue growth for Abecma, improved margins, and significant cost reductions. The strategic focus on Abecma and partnerships with Regeneron and Novo Nordisk are promising. Despite competitive pressures and seasonality, the company anticipates breakeven by 2025, with a reduced breakeven point. The Q&A highlights strong demand and improved manufacturing capacity. While there are risks, the overall sentiment is positive, suggesting a likely stock price increase.
Key Financial Performance
U.S. Abecma Revenues $77 million, which reflects a 42% growth over the prior quarter.
Collaborative Arrangement Revenue Approximately $11 million related to the collaboration with BMS.
GAAP Operating Expenses $10 million reduction or 24% versus the prior quarter, and a $140 million reduction or 52% year-to-date versus the same period last year, primarily driven by a reduction in R&D expenses.
Net Cash Spend Expected in the range of $40 million to $60 million for 2024.
Burn Rate Approximately $10 million this quarter.
Breakeven Sales Point Estimated closer to $300 million for total U.S. sales.
Operating Highlights
Abecma U.S. Revenues: Third quarter U.S. revenues for Abecma grew 42% over the prior quarter, totaling $77 million.
FDA Approval: Received FDA approval in the third-line setting, expanding Abecma's availability to more patients with multiple myeloma.
Market Positioning: Abecma is positioned in a growing CAR-T market, with a differentiated safety profile and competitive efficacy.
Revenue Guidance: Expected U.S. Abecma revenues for 2024 are approximately $240 million to $250 million.
Cost Structure Optimization: Achieved a $10 million or 24% reduction in GAAP operating expenses versus the prior quarter.
Employee Reduction: Reduced workforce from 277 employees at the end of 2023 to 70 employees.
Strategic Focus: Streamlined operations focusing exclusively on Abecma, aiming for breakeven operations by 2025.
Discontinued Study: Decision to discontinue enrollment in the KarMMa-9 study to maintain financial discipline.
Risk or Challenges
Competitive Pressures: The multiple myeloma market is dynamic and competitive, with expectations of continued competition impacting U.S. Abecma revenues, particularly in the fourth quarter due to a reduction in CAR-T infusion schedules during the holiday season.
Regulatory Issues: The company has received FDA approval for Abecma in the third-line setting, which is crucial for expanding its market reach.
Supply Chain Challenges: The company is working with Bristol-Myers Squibb to streamline expenses across clinical, manufacturing, and commercial operations, indicating potential supply chain challenges.
Economic Factors: The company has a significant reduction in operating expenses, with a $10 million or 24% reduction in GAAP operating expenses versus the prior quarter, and a $140 million or 52% year-to-date reduction, reflecting economic pressures.
Financial Discipline: The decision to discontinue enrollment in the KarMMa-9 study exemplifies the financial discipline being applied to manage costs effectively.
Burn Rate: The company reported a burn rate of approximately $10 million this quarter, down from $63 million in the fourth quarter of 2023, indicating improved financial management.
Guidance & Outlook
Sale of Oncology and Autoimmune R&D Pipeline: Successfully completed the sale to Regeneron, including about 160 employees and the majority of real estate footprint.
Sale of Hemophilia A Program: Sold to Novo Nordisk for $40 million.
FDA Approval for Abecma: Received approval in the third-line setting, expanding availability to more patients.
Focus on Abecma: Streamlined operations to focus exclusively on Abecma, aiming for breakeven operations.
Cost Structure Optimization: Working on optimizing the cost structure to increase operating margin and cash flow.
Discontinuation of KarMMa-9 Study: Decision made to apply financial discipline across the business.
2024 U.S. Abecma Revenue Guidance: Expected to be approximately $240 million to $250 million.
Fourth Quarter Revenue Impact: Expected impact from competition and reduced CAR-T infusion schedules during the holiday season.
Operating Expenses Reduction: Achieved a $10 million reduction in GAAP operating expenses in Q3, with a 52% year-to-date reduction.
Net Cash Spend Guidance: Expected in the range of $40 million to $60 million for 2024.
Breakeven Sales Point: Estimated closer to $300 million for total U.S. sales.
Cash Runway: Projected to extend beyond 2027.
Shareholder Return Plan
Collaborative Arrangement Revenue: In the third quarter, we reported collaborative arrangement revenue of approximately $11 million related to our collaboration with BMS.
Expected U.S. Abecma Revenues for 2024: We expect U.S. Abecma revenues to be approximately $240 million to $250 million for 2024.
Breakeven Sales Point: In the past, we've guided to about $400 million being the breakeven sales point for total U.S. sales, but we think it's closer to $300 million as we sit here today.
Net Cash Spend for 2024: We continue to expect net cash spend in the range of $40 million to $60 million for 2024.
Key Q&A
Earnings Word Cloud
TSVT Transcript
The earnings call reflects strong financial performance with a 42% revenue growth for Abecma, improved margins, and significant cost reductions. The strategic focus on Abecma and partnerships with Regeneron and Novo Nordisk are promising. Despite competitive pressures and seasonality, the company anticipates breakeven by 2025, with a reduced breakeven point. The Q&A highlights strong demand and improved manufacturing capacity. While there are risks, the overall sentiment is positive, suggesting a likely stock price increase.
The earnings call presents a positive sentiment with a focus on strategic realignment and a leaner cost structure. Despite regulatory and market risks, the company achieved profitability and reduced operating expenses significantly. The Q&A section highlights positive early experiences with ABECMA and potential growth. While guidance is not yet provided, the revised net cash spend range and expectation of breakeven by 2025 are promising. The stock price is likely to see a positive movement, considering the reduced financial risk and operational efficiency improvements.
The earnings call reveals several challenges: declining revenues due to competition, regulatory hurdles, and limited patient access. Restructuring efforts aim to save costs, but involve significant one-time expenses, creating short-term financial strain. While ABECMA's safety and efficacy are competitive, the market remains challenging. Despite potential growth from label expansion, the current competitive pressure and regulatory complexities present risks. The Q&A section further highlights management's vague responses on utilization trends, adding to uncertainties. These factors suggest a negative outlook for the stock price in the short term.
TSVT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
